JP2023504143A5 - - Google Patents

Info

Publication number
JP2023504143A5
JP2023504143A5 JP2022532095A JP2022532095A JP2023504143A5 JP 2023504143 A5 JP2023504143 A5 JP 2023504143A5 JP 2022532095 A JP2022532095 A JP 2022532095A JP 2022532095 A JP2022532095 A JP 2022532095A JP 2023504143 A5 JP2023504143 A5 JP 2023504143A5
Authority
JP
Japan
Prior art keywords
hydrogen
nhr
alkyl
aryl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022532095A
Other languages
English (en)
Japanese (ja)
Other versions
JP7760167B2 (ja
JP2023504143A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/083597 external-priority patent/WO2021105335A1/en
Publication of JP2023504143A publication Critical patent/JP2023504143A/ja
Publication of JP2023504143A5 publication Critical patent/JP2023504143A5/ja
Application granted granted Critical
Publication of JP7760167B2 publication Critical patent/JP7760167B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022532095A 2019-11-27 2020-11-27 セレブロンに結合するピペリジン-2,6-ジオン誘導体、及びその使用方法 Active JP7760167B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLPCT/PL2019/000108 2019-11-27
PL2019000108 2019-11-27
PCT/EP2020/083597 WO2021105335A1 (en) 2019-11-27 2020-11-27 Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023504143A JP2023504143A (ja) 2023-02-01
JP2023504143A5 true JP2023504143A5 (cg-RX-API-DMAC10.html) 2023-12-05
JP7760167B2 JP7760167B2 (ja) 2025-10-27

Family

ID=69024571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022532095A Active JP7760167B2 (ja) 2019-11-27 2020-11-27 セレブロンに結合するピペリジン-2,6-ジオン誘導体、及びその使用方法

Country Status (4)

Country Link
US (1) US20230065745A1 (cg-RX-API-DMAC10.html)
EP (1) EP4065576A1 (cg-RX-API-DMAC10.html)
JP (1) JP7760167B2 (cg-RX-API-DMAC10.html)
WO (1) WO2021105335A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022255888A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
CN113501807A (zh) * 2021-06-10 2021-10-15 重庆科技学院 四氢苯并噻吩类化合物及药物组合物的制备方法和用途
WO2023049919A1 (en) * 2021-09-27 2023-03-30 The Trustees Of The University Of Pennsylvania Inhibitors of molluscum contagiosum infection and methods using the same
WO2023101556A1 (en) * 2021-12-02 2023-06-08 Rijksuniversiteit Groningen Novel inhibitors of aspartate transcarbamoylase (atcase) and compositions, methods and uses related thereto.
AU2023403190A1 (en) * 2022-12-02 2025-07-17 Aten Porus Lifesciences Pvt. Ltd. Adar1 inhibitors and methods of using the same
JP2025540970A (ja) * 2022-12-06 2025-12-17 キャプター セラピューティクス エス.エー. ユビキチンリガーゼ及びターゲットmcl-1タンパク質に結合する二機能性化合物を使用するターゲティングされたタンパク質分解
WO2024123195A1 (en) * 2022-12-06 2024-06-13 Captor Therapeutics S.A. Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
JP2002105073A (ja) * 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
AU2007290407A1 (en) 2006-08-30 2008-03-06 Celgene Corporation 5-substituted isoindoline compounds
WO2008033562A2 (en) * 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds
HUE035389T2 (en) 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
CN109153644B (zh) 2016-03-16 2022-10-21 H·李·莫菲特癌症中心研究有限公司 用以增强效应t细胞功能的针对cereblon的小分子
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
JP7258009B2 (ja) 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
US10584133B2 (en) * 2018-03-30 2020-03-10 Biotheryx, Inc. Thienopyrimidinone compounds

Similar Documents

Publication Publication Date Title
JP2024520481A5 (cg-RX-API-DMAC10.html)
DE69422163T2 (de) Glycerolderivat, vorrichtung und pharmazeutische zusammensetzung
RU2403258C2 (ru) Тиазолилдигидроиндазолы
JP2022545359A5 (cg-RX-API-DMAC10.html)
JP2024501537A5 (cg-RX-API-DMAC10.html)
JP2025505644A5 (cg-RX-API-DMAC10.html)
JP2017511360A5 (cg-RX-API-DMAC10.html)
RU2006109491A (ru) Новые трициклические нуклеозиды или нуклеотиды в качестве терапевтических средств
JP2021507895A5 (cg-RX-API-DMAC10.html)
JPH10506619A (ja) ウィルス感染を治療するための脂質アナログ
RU2017112048A (ru) Синергистические комбинации ауристана
JP2016516068A5 (cg-RX-API-DMAC10.html)
JP2025505994A5 (cg-RX-API-DMAC10.html)
PT100199B (pt) Combinacao antiviral de nucleosidos e processo para a sua preparacao
JP2020507589A5 (cg-RX-API-DMAC10.html)
RU2008108887A (ru) Жидкие составы
JP2023535815A5 (cg-RX-API-DMAC10.html)
JP2025507292A5 (cg-RX-API-DMAC10.html)
JP2023504445A5 (cg-RX-API-DMAC10.html)
JP2024521895A5 (cg-RX-API-DMAC10.html)
AR045040A1 (es) Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos
JP2025505200A5 (cg-RX-API-DMAC10.html)
JP2001510843A5 (cg-RX-API-DMAC10.html)
JP2020532562A5 (cg-RX-API-DMAC10.html)
JP2019501881A (ja) がんに対するメルフルフェン投薬計画